SEC Comment Letter 0000000000-24-006938 to Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc.
Date: June 17, 2024 · CIK: 0001623526 · Accession: 0000000000-24-006938
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280172
Letter
United States securities and exchange commission logo June 17, 2024 Edward Kaye Chief Executive Officer Stoke Therapeutics, Inc. 45 Wiggins Avenue Bedford, MA 01730 Re:Stoke Therapeutics, Inc. Registration Statement on Form S-3 Filed June 13, 2024 File No. 333-280172 Dear Edward Kaye: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Julia Forbess
Show Raw Text
United States securities and exchange commission logo
June 17, 2024
Edward Kaye
Chief Executive Officer
Stoke Therapeutics, Inc.
45 Wiggins Avenue
Bedford, MA 01730
Re:Stoke Therapeutics, Inc.
Registration Statement on Form S-3
Filed June 13, 2024
File No. 333-280172
Dear Edward Kaye:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Julia Forbess